The mistake we're making about essential oils ...

A Constituent-Based Analysis Revealing the Need for Biochemical Personalization

The Lavender Paradox

Let me share something that might surprise you: when someone recommends “lavender for sleep,” they’re making essentially the same recommendation as suggesting coriander seed, orange leaf, rosewood or clary sage. Each of these oils contain 50-70% linalool—the same chemical constituent responsible for the calming effect.

Yet you’ve probably never heard anyone say, “Just inhale some coriander seed before bed.”

This isn’t a quirk of aromatherapy education. It’s a symptom of a much larger problem: we’ve been suggesting essential oils with an allopathic, ‘conventional mindset’, by their names rather than their chemistry/synergy.

And when we examine the actual chemical compounds that determine synergistic effects, we discover something extraordinary—and deeply troubling about current aromatherapy practice.

The Species-Based Paradigm

For decades, aromatherapy education has operated on a simple premise: memorize which oils do what.

• Lavender for sleep

• Peppermint for headaches

• Tea tree for infections

• Eucalyptus for congestion

• Geranium for hormones

• Frankincense for meditation

These recommendations are passed from teacher to student, repeated in books and courses, and accepted as foundational truths. We learn the properties of 50, 100, or even 200 different essential oils, each with its own list of traditional uses, energetic qualities, and therapeutic applications.

But here’s what this paradigm ignores: essential oils aren’t single substances. They’re complex mixtures of chemical constituents—and the synergy between every constituent determines what an oil actually does in the body.

The plant name on the bottle identifies a species (more or less). It doesn’t tell you what’s biochemically active inside it.

Opening the Black Box: What’s Really Inside

When we analyze essential oil composition using gas chromatography-mass spectrometry (the industry standard), we discover that oils are typically composed of 50-300+ different chemical constituents. A few major constituents make up 60-90% of the oil, with dozens of minor and trace constituents not only filling out the profile, but also contributing the systemic benefits of that oil.

It’s these chemical constituents—not the Latin botanical name—that interact with olfactory receptors, cell membranes, neurotransmitter systems, and gene expression pathways throughout the body.

And here’s where it gets interesting: the same beneficial constituents appear in dozens of different essential oils.

The authoritative text Essential Oil Safety by Robert Tisserand and Rodney Young (2nd edition) contains 206 constituent profiles, each cross-referenced across 400 essential oil profiles. This comprehensive analysis reveals something the aromatherapy industry rarely discusses openly:

Most major therapeutic constituents are found in 20-50 different essential oils, often at dramatically varying concentrations.

Let me show you what this actually looks like.

Exhibit A: The Linalool Files

Linalool is a monoterpene alcohol widely recognized for its calming, anxiolytic, and sedative properties. It’s often cited as the reason lavender oil promotes relaxation and sleep.

Here’s what studies reveal about linalool distribution:

Linalool Content Across Essential Oils:

Highest Concentrations:

• Coriander seed: 60-80%

• Orange leaf (bigarade): 51.0–71.0%

• Clary sage: 45.3–73.6%

• Rosewood: 80-90%

• Ho wood: 80-99%

• Mint (bergamot): 34.0–57.3%

Moderate Concentrations:

• Lavender (true): 20-45%

• Lavandin: 25-40%

• Sweet basil: 25-45%

• Clary sage: 10-25%

• Petitgrain: 10-25%

Lower Concentrations:

• Bergamot: 5-15%

• Neroli: 10-20%

• Ylang-ylang: 5-15%

Notice anything peculiar?

Coriander seed contains more linalool than lavender. Often significantly more. Yet coriander seed isn’t marketed for sleep. It’s typically discussed in the context of digestion or as a spice oil.

Ho wood contains up to 99% linalool—more than twice the concentration found in most lavenders. It’s essentially purified linalool in a plant matrix. Yet it remains relatively unknown compared to lavender.

If linalool is the constituent responsible for calming effects, why aren’t we recommending the oils with the highest linalool content?

Because we’re not thinking about constituents. We’re thinking about pleasant aromas and marketing narratives.

Exhibit B: The Limonene Illusion

Limonene (specifically d-limonene) is the most common essential oil constituent globally. It’s found in virtually every citrus oil and appears across dozens of non-citrus species.

Limonene Distribution:

Citrus Oils:

• Clementine: 94.8–95.0%

• Grapefruit: 84.8–95.4%

• Orange (sweet): 83.9–95.9%

• Tangerine: 87.4–91.7%

• Mandarin: 65-75%

• Lemon: 56.6–76.0%

• Bergamot: 30-50%

Non-Citrus Oils:

• Dill seed: 30-50%

• Caraway: 50-70%

• Celery seed: 60-70%

• Elemi: 26.9-65%

• Fleabane: 56.2%

• Black pepper: 15-25%

• plus over 100 more!

Here’s the problem: we assign different emotional and beneficial properties to these oils despite the shared chemistry.

Sweet orange is “uplifting.” Grapefruit is “energizing.” Lemon is “cleansing.” Mandarin is “calming.”

But they all contain 85-95% of the same constituent.

The 5-15% of minor constituents create subtle changes to the aroma and alter the properties, yet the major biochemical actor—the molecule actually binding to receptors and influencing physiology—is identical.

The important question then becomes, ‘if these oils are chemically similar, why do they supposedly have different effects?’

The answer is uncomfortable: one essential oil is a single recipe of constituents. Outcomes vary when you swap out ingredients.

Exhibit C: Beta-Caryophyllene’s Identity Crisis

Beta-caryophyllene is a sesquiterpene that functions as a selective CB2 receptor agonist—meaning it activates cannabinoid receptors involved in pain perception, inflammation, and immune function without psychoactive effects.

This is remarkable pharmacology with clear therapeutic implications. Yet look at how beta-caryophyllene-rich oils are marketed:

Beta-Caryophyllene Content Across Categories:

“Pain Relief” Oils:

• Copaiba: 24.7–53.3%

“Digestive Support” Oils:

• Black pepper: 9.4–30.9%

“Romantic/Aphrodisiac” Oils:

• Ylang-ylang: 1.1–21.5%

“Stress Relief” Oils:

• Melissa: 0.3–19.1%

“Anti-inflammatory” Oils:

• Clove: 5-12%

“Grounding” Oils:

• Frankincense carterii: 1.9-7.5%

• Lavender: 1.8–5.9%

Same constituent. Different purposes.

If beta-caryophyllene activates CB2 receptors—which we know it does—then all of these oils share that mechanism. The therapeutic effect is determined by the constituent’s biochemical synergy, not by which plant produced it or what tradition assigned it.

So why does copaiba get marketed specifically for pain when black pepper can contain almost as much beta-caryophyllene? Why is ylang-ylang linked to romance when it contains the same anti-inflammatory constituent as clove?

Because we’re not listening to our body’s needs. We’re listening to popular suggestions.

Yet, to be fair, common use categories were developed long before we understood receptor pharmacology or could analyze chemical composition. But now that we know … it’s imperative we shift our thinking.

The Geranium Irony

Let’s examine one more example that illustrates how backwards our naming and marketing systems are.

Geranium oil (Pelargonium graveolens) is widely known for its distinctive rosy aroma, often attributed to its geraniol content. The plant genus and common name both derive from this characteristic constituent.

Here’s the actual geraniol data:

Geraniol Content:

• Wild bergamot: 86.8–93.2%

• Jamrosa: 54.0–85.0%

• Palmarosa: 70-85%

• Citronella (Sri Lankan): 16.8–29.1%

• Rose (Damask): 2.1–25.7%

• Geranium: 7.3–30.3%

Geranium contains LESS geraniol than multiple other oils.

Wild bergamot contains three times as much geraniol as many geranium oils. Yet geranium gets the name recognition, the association with the constituent, and the marketing around its “geraniol properties.”

If you want geraniol—for its antimicrobial effects, its skin benefits, or its aroma—you’d be better served by palmarosa or jamrosa. But those oils lack the name recognition and traditional narrative.

The marketing and the chemistry don’t align.

The Chemotype Problem

The situation becomes even more complex when we consider chemotypes—chemical varieties within the same botanical species.

Rosemary: One Species, Three Chemistries

Rosemary (Rosmarinus officinalis) exists in at least three distinct chemotypes:

Cineole Chemotype:

• 40-50% 1,8-cineole (eucalyptol)

• Used for: Respiratory support, mental clarity

Camphor Chemotype:

• 15-25% camphor

• Used for: Muscular pain, circulation

Verbenone Chemotype:

• 15-25% verbenone

• Used for: Skin regeneration, mucolytic

These aren’t three different species. They’re the same plant, growing in different environments, producing completely different chemical profiles—with completely different safety considerations and therapeutic applications.

You cannot recommend “rosemary” without specifying which chemotype.

• How many aromatherapy books, courses, and reference guides make this distinction?

• How many practitioners ask suppliers which chemotype they’re purchasing?

• How many users have any idea that the “rosemary” they bought online might be drastically different from what they used last year?

• How many know that the ‘recommended’ rosemary is not the chemotype their company carries?

Thyme: Seven Chemical Identities

Thyme (Thymus vulgaris) exists in at least seven chemotypes:

1. Thymol CT: 48.3–62.5% thymol (antimicrobial but dermally irritating)

2. Carvacrol CT: Similar properties to thymol

3. Linalool CT: 1.0–3.8% thymol, much gentler

4. Geraniol CT: Different therapeutic profile entirely

5. Thujanol CT: Rare, highly valued

6. 1,8-Cineole CT: Respiratory-focused

7. Limonene CT: Citrus-like chemistry

Same species. Same Latin name. Seven dramatically different chemical compositions.

One chemotype (thymol) is a potent antimicrobial that requires careful dilution and has multiple contraindications. Another (linalool) is gentle enough for children and contains entirely different active constituents.

Recommending “thyme” without chemotype specification is biochemically meaningless and potentially unsafe.

The Concentration Question

Even when we identify the right constituent in the right oil, we face another complication: concentration varies dramatically.

Alpha-Pinene Across the Spectrum:

• Turpentine: 44.1–94.3%

• Ferula: 79.5%

• Boswellia frereana: 41.7–80.0%

• Pine species: 20-60%

• Cypress: 15-45%

• Rosemary: 15-25%

• Black pepper: 10-20%

• Tea tree: 2-8%

If alpha-pinene is the therapeutic target—for its anti-inflammatory effects, its bronchodilator properties, or its mental clarity benefits—then dose matters immensely.

A 2% concentration in tea tree delivers entirely different exposure than an 80% concentration in frankincense. Yet both are recommended for “respiratory support” without distinguishing the massive difference in active constituent delivery.

Effects are synergy-dependent. Constituent concentration affects synergy.

This means that the therapeutic outcome depends not just on selecting the right constituent, but on:

• Knowing its concentration in the chosen oil

• Understanding the required dose for effect

• Matching that dose to the individual’s biochemical response threshold

None of this is captured by saying “use frankincense for breathing.”

The Eucalyptus Everywhere Problem

1,8-Cineole (eucalyptol) is so strongly associated with Eucalyptus that it’s literally called “eucalyptol.” It’s the defining constituent of eucalyptus oils, responsible for their characteristic aroma and their respiratory benefits.

Here’s what we don’t usually discuss: 1,8-cineole appears in 30+ non-eucalyptus oils.

1,8-Cineole Distribution:

Very High Concentration:

• Eucalyptus globulus: 60-85%

• Eucalyptus radiata: 60-75%

• Cardamom: 30-45%

• Rosemary (cineole CT): 40-50%

• Bay laurel: 35-50%

High Concentration:

• Cajeput: 45-55%

• Niaouli: 50-65%

• Ravensara: 50-60%

Moderate Concentration:

• Tea tree: 5-15%

• Sage: 5-15%

If you need 1,8-cineole—for its mucolytic properties, its ability to increase ciliary beat frequency, or its antimicrobial effects—you have at least a dozen viable options beyond eucalyptus.

Bay laurel contains as much 1,8-cineole as many eucalyptus species. Cardamom provides significant amounts. Rosemary cineole chemotype rivals eucalyptus.

The beneficial constituent transcends the species.

Yet we continue to recommend “eucalyptus for congestion” as if eucalyptus has some unique property that other 1,8-cineole-rich oils lack. It doesn’t. The chemistry is transferable.

The Safety Implications

This constituent-level analysis has profound safety implications that the species-based paradigm obscures.

Case Study: Camphor Neurotoxicity

Camphor is a monoterpene ketone with known neurotoxic potential. At high doses, it can cause seizures. This is well-documented.

The safety concern isn’t whether the camphor comes from:

• Ho Leaf (42-84% camphor)

• Camphor oil (40-50% camphor)

• Rosemary camphor CT (15-25% camphor)

• Spike lavender (8-16% camphor)

• Sage (20-35% camphor)

• Lavandin Grosso (6.6-12.2%)

The safety concern is camphor concentration and total dose.

If someone is told to avoid camphor oil due to seizure risk, but then uses large amounts of spike lavender (thinking it’s safe because it’s “lavender”), or lavandin grosso (because it’s commonly substituted for lavender in body care products), they’re still getting camphor exposure.

The risk follows the constituent, not the bottle label.

Case Study: Hepatotoxic Constituents

Three constituents—estragole, methyleugenol, and safrole—are classified as potential hepatocarcinogens based on rodent studies. Regulatory agencies have set strict limits on their use.

These constituents appear in multiple oils:

Estragole:

• Basil (estragole CT): 70-85%

• Tarragon: 60-75%

• Fennel: 2-5%

• Star anise: 1-5%

Methyleugenol:

• Basil (methyleugenol CT): 40-70%

• Nutmeg: 0-3%

• Bay laurel: 1-4%

Safrole:

• Sassafras: 80-90%

• Camphor (brown): 5-80%

• Various others: Trace amounts

If you’re avoiding sassafras due to safrole content, but using large amounts of basil oil high in estragole or methyleugenol, you’re still getting hepatotoxic constituent exposure.

The mechanism is the same. The risk is comparable. The safety limits should be based on constituent exposure, not on which plant produced it.

This is why constituent-based thinking isn’t just more accurate—it’s safer.

What Biochemical Individuality Really Means

Here’s where the story gets even more complex—and more fascinating.

Even if we correctly identify therapeutic constituents and match them to oils with appropriate concentrations, we still face a fundamental truth: people respond differently to the same constituents.

This isn’t just about preference or placebo. It’s about:

• Genetic polymorphisms affecting olfactory receptors

• Variations in metabolic enzymes that process constituents differently

• Differences in receptor density and sensitivity across tissues

• Individual histories of exposure create unique scent-memory associations

• Current physiological states affecting how constituents are processed

• Ectopic olfactory receptor expression patterns throughout the body

Two people can inhale the same linalool-rich oil and have completely different physiological responses because their bodies process and respond to linalool differently.

One person’s “calming” oil might create agitation in another. One person’s “energizing” blend might induce fatigue in someone else.

This is why generic recommendations fail even when we get the chemistry right.

The biochemistry is just the starting point. Individual response is where personalization becomes essential.

The Myth of “Synergy” as Justification

When confronted with this constituent data, defenders of species-based aromatherapy often invoke “synergy”—the idea that whole essential oils work differently than isolated constituents because of complex interactions among the 50-300 compounds present.

This is a valid scientific concept. Synergistic interactions do occur. Minor constituents can modulate major constituent effects. The whole is sometimes different from the sum of its parts.

But here’s the problem: synergy doesn’t justify ignoring constituent composition.

If synergy explains property differences, then:

1. We should be able to demonstrate how the minor constituents in lavender create synergies that don’t occur in coriander seed (despite similar linalool content)

2. We should understand which specific constituent combinations produce which synergistic effects

3. We should be able to predict synergy based on composition analysis

We can’t do any of these things systematically.

“Synergy” has become a catch-all explanation that allows us to avoid the uncomfortable reality that much of traditional aromatherapy practice is based on narrative rather than chemistry.

Does synergy exist? Absolutely.

Does it justify recommending “lavender” without knowing its linalool content, without understanding if the individual responds to linalool, and without comparing it to other linalool sources? No.

Synergy is real. Using synergy to avoid constituent analysis is intellectually dishonest.

Why This Matters

If you’ve stayed with me through all this data, you might be wondering: why does it matter? If traditional recommendations work for some people, why does it matter whether we understand the chemistry correctly?

It matters for several reasons:

1. Efficacy

When we select oils by name rather than chemistry, we’re guessing. Sometimes we guess right. Often we don’t.

If someone needs linalool but we give them a low-linalool lavender when a high-linalool coriander would work better, we’ve failed them—even though we followed traditional recommendations.

If someone doesn’t respond to linalool at all, but we keep trying different “calming” oils that all contain linalool, we’re wasting their time and money chasing the wrong chemistry.

Understanding constituents dramatically improves our ability to match beneficial solutions to individual needs.

2. Safety

Species-based thinking obscures constituent-based risks. If someone has a contraindication to camphor, they need to avoid ALL high-camphor oils, not just the one labeled “camphor.”

If someone is on blood thinners, they need to know about coumarin content across multiple oils, not just avoid “cinnamon bark.”

Safety requires constituent literacy.

3. Cost Effectiveness

When a rare, expensive oil contains the same constituents as a common, affordable one, why are we recommending the expensive version?

Rose absolute is beautiful and precious—but if you need geraniol, palmarosa costs 5% as much and contains twice the concentration.

Sandalwood (East Indian) faces sustainability concerns and extreme costs—but if you need santalols for their CB2 agonist effects, Australian sandalwood provides similar chemistry at lower cost and environmental impact.

Constituent-based thinking opens options.

4. Environmental Ethics

When we recommend oils based on tradition rather than chemistry, we create demand for endangered species unnecessarily.

Rosewood (Aniba rosaeodora) has faced overharvesting. Yet ho wood provides nearly identical chemistry from a more sustainable source.

Certain frankincense species are threatened. Understanding that alpha-pinene and other key constituents appear in abundant species like galbanum and pine allows us to preserve rare resources for uses where they’re truly irreplaceable.

Constituent knowledge supports sustainability.

5. Professional Credibility

When aromatherapists make constituent-ignorant recommendations, we undermine professional credibility. Scientists, physicians, and pharmacologists can see the logical gaps.

If we want aromatherapy to be taken seriously as a modality of integrity, we need to think and speak biochemically.

Constituent literacy elevates the profession.

The Uncomfortable Truth

The aromatherapy industry has built itself on species names, traditional uses, and emotional narratives. Entire product lines, certification courses, and reference books organize information around botanical names and traditional properties.

This analysis threatens that structure.

If the benefits lie in constituents rather than species, then:

• Product marketing must change

• Education must be restructured

• Reference materials must be rewritten

• Practitioner training must emphasize chemistry

• Consumers must learn new evaluation criteria

The industry has strong incentives to resist this shift.

But resistance doesn’t change the chemistry. Limonene is limonene whether it comes from orange or dill. Linalool functions the same way whether extracted from lavender or coriander. Beta-caryophyllene activates CB2 receptors consistently across all source species.

The chemistry is indifferent to our beliefs, our marketing, and our resistance.

We can continue teaching and practicing aromatherapy as if species names determined properties. Or we can align our practice with biochemical reality.

The data is clear. The choice is ours.

What This Means for Practice

I’m not suggesting we abandon essential oils or dismiss traditional wisdom entirely. Plants have been healing humans for millennia, and that empirical knowledge has value.

But we need to fundamentally reorient how we think about and use these powerful botanical extracts.

Instead of memorizing that “lavender is calming,” we need to understand that:

• Linalool and linalyl acetate have anxiolytic properties

• These constituents appear in multiple species at varying concentrations

• Individual response to these constituents varies based on genetics and receptor expression

• The optimal source and concentration depend on the individual’s unique biochemistry

Instead of recommending “tea tree for infections,” we need to recognize that:

• Terpinen-4-ol is the primary antimicrobial constituent

• Multiple oils contain terpinen-4-ol at therapeutic levels

• The target pathogen and site of infection affect constituent selection

• Individual immune status and previous exposure history influence outcomes

This is what constituent-based, biochemically individualized aromatherapy looks like.

It’s more complex. It requires more knowledge. It demands chemical literacy and analytical thinking.

But it’s also more effective, safer, more sustainable, and more honest about what we’re actually doing when we use these remarkable plant medicines.

Where Do We Go From Here?

This analysis reveals a field at a crossroads. We can continue with species-based traditional practice, or we can evolve toward constituent-based personalized aromatherapy.

The former is easier, more marketable, and consistent with current industry infrastructure.

The latter is more accurate, more effective, and more aligned with scientific understanding of how these substances actually work in human biochemistry.

Both approaches will continue to coexist. Traditional aromatherapy isn’t disappearing. But practitioners and users who want to work at the cutting edge—who want to achieve consistent, predictable, individualized results—must shift toward constituent-based thinking.

This means:

For Practitioners:

• Learning constituent pharmacology

• Requesting and reviewing GC-MS analyses

• Understanding chemotype variations

• Developing assessment methods for individual biochemical needs

• Thinking in terms of “this person needs these constituents” rather than “this condition requires this oil”

For Educators:

• Restructuring curricula around constituent families

• Teaching chemistry before traditional uses

• Incorporating genetic and biochemical individuality

• Preparing students for analytical rather than memorization-based practice

For the Industry:

• Transparent constituent disclosure on all products

• Chemotype specification for variable species

• Marketing based on chemistry rather than tradition

• Supporting research into constituent mechanisms and individual variability

For Users:

• Learning to read constituent profiles

• Understanding that your biochemistry is unique

• Recognizing that what works for others may not work for you

• Expecting evidence rather than accepting traditional claims

The Foundation for What’s Next

The data presented here—drawn from the definitive safety reference in our field—proves beyond reasonable doubt that generic, species-based essential oil recommendations are biochemically indefensible.

The same therapeutic constituents appear in dozens of different oils. Concentrations vary dramatically. Chemotypes create multiple chemical identities within single species. Individual biochemistry determines response.

These facts aren’t controversial. They’re documented in the very books we use to certify practitioners and establish safety guidelines.

What’s controversial is acknowledging what these facts mean: conventional aromatherapy practice needs fundamental restructuring.

Not abandonment. Not dismissal. But evolution toward a model that honors both the wisdom of traditional use and the precision of biochemical understanding.

The chemistry has been speaking all along. We’ve just been too attached to our narratives to listen.

It’s time to let the constituents tell their story.

[Author note: The implications of this analysis and the methodology for constituent-based personalized aromatherapy selection will be addressed in subsequent articles. This piece establishes the evidentiary foundation showing why such an approach is necessary.]

About the Author

Tammy is a Clinical Neuroaromatherapist with nearly 40 years of experience spanning pharmacology, neuroscience, epigenetics, psychology, and essential oil chemistry. She serves as a peer reviewer for pharmacology journals and is the founder of Aromagenomics, where she has developed the ANIS (Aromatic Neural Integrative System)™️. She is currently working on her book, “Follow Your Nose: From Plant Wisdom to Personal Power.”